Financials in USD. Standardized financial statements.
A compact view of how Karuna Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Revenue? | $654,000 | $10.64M | $36.96M | $0 | $0 | $0 | $0 |
| Revenue Growth? | -93.9% | -71.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.70M | $1.11M | $506,000 | $145,000 | $58,000 | $0 | $0 |
| Gross Profit? | -$1.05M | $9.53M | $36.46M | -$145,000 | -$58,000 | $0 | $0 |
| Gross Margin? | -160.1% | +89.5% | +98.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $495.43M | $300.31M | $180.82M | $71.82M | $45.41M | $14.51M | $4.81M |
| Operating Income? | -$494.78M | -$289.68M | -$143.85M | -$71.82M | -$45.41M | -$14.51M | -$4.81M |
| EBITDA? | -$493.08M | -$259.63M | -$143.15M | -$68.51M | -$42.88M | -$14.48M | -$4.80M |
| Income Before Tax | -$433.01M | -$274.92M | -$143.80M | -$68.51M | -$43.96M | -$17.51M | -$6.03M |
| Income Tax Expense | $670,000 | $1.42M | $6,000 | $43,000 | $887,000 | $0 | $0 |
| Net Income? | -$433.68M | -$276.34M | -$143.81M | -$68.55M | -$44.84M | -$17.51M | -$6.03M |
| EPS? | $-11.73 | $-8.74 | $-4.94 | $-2.59 | $-3.75 | $-1.61 | $-0.81 |
| Diluted EPS? | $-11.73 | $-8.74 | $-4.94 | $-2.59 | $-3.75 | $-1.61 | $-0.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality